GLPGF — Lakefront Biotherapeutics NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421876 ·
Belgium
Last close
$28.08
Market Cap
$1.85B
52W High
$33.27
52W Low
$28.08
ADV30
37
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,481,000 | 1,682,000 | -63,703,000 | 14,492,000 | 3,372,429,000 | 66,805,000 | 119,060,000 |
| Dec 2025 | 900,822,000 | 900,367,000 | 758,798,000 | 782,146,000 | 3,406,518,000 | 87,868,000 | 170,650,000 |
| Sep 2025 | 71,161,000 | 60,315,000 | -41,672,000 | -202,111,000 | 3,511,914,000 | 64,458,000 | 1,064,951,000 |
| Jun 2025 | 65,288,000 | 60,582,000 | -57,027,000 | -105,748,000 | 3,818,224,000 | 71,669,000 | 1,174,405,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-301,599,000
Investing CF
$265,566,000
Financing CF
$-2,772,000
CapEx
$-8,732,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$228,331,000
Inventory
$17,693,000
Receivables
$54,034,000
ST Investments
$2,915,435,000
EBIT TTM
$398,093,000
Pretax Income TTM
$471,194,000
Interest Exp TTM
$792,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,043,752,000
EBITDA
$662,956,480
Free Cash Flow
$210,970,496
Enterprise Value
$-1,125,415,296
Total Cash
$2,982,240,000
Total Debt
$6,435,000
Shares Out
65,897,071
Trailing EPS
$8.61
Book Value
$57.80
ROE
16.3%
ROA
10.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,112,248,000 | 501,391,000 | 320,884,000 | 3,406,518,000 | 170,650,000 | — | -257,456,000 |
| Dec 2024 | 275,649,000 | -188,338,000 | 74,082,000 | 4,135,719,000 | 1,238,780,000 | — | -320,026,000 |
| Dec 2023 | 239,724,000 | -88,263,000 | 211,697,000 | 4,357,396,000 | 1,561,830,000 | — | -405,970,000 |
| Dec 2022 | 241,249,000 | -131,057,000 | -217,991,000 | 4,734,351,000 | 2,208,325,000 | — | -500,544,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANIP | ANI PHARMACEUTICALS INC | $1.85B | $81.41 | — |
| ZYME | Zymeworks Inc. | $1.85B | $25.40 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.86B | $2.16 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $1.88B | $17.00 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.88B | $20.13 | — |
News headlines (Yahoo Finance, 1h cache)
Galapagos Q1 Earnings Call Highlights
2026-05-07 20:58 · Yahoo
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:01 · Yahoo
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
2026-04-28 20:01 · Yahoo
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
2026-04-24 13:43 · Yahoo
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
2026-04-04 12:16 · Yahoo
Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials
2026-03-31 13:26 · Yahoo
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
2026-03-31 08:16 · Yahoo
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
2026-03-31 05:30 · Yahoo
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
2026-03-27 00:55 · Yahoo
Galapagos Announces Nomination of Gino Santini to its Board of Directors
2026-03-26 20:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.